Vietnam’s diagnostic laboratory industry may represent a significantly larger investment opportunity than many healthcare investors realise.
According to market research published by Ken Research in July 2026, Vietnam’s diagnostic laboratory market was estimated at US$1.12 billion in 2025 and is projected to reach approximately US$1.83 billion by 2031.
That represents compound annual growth of around 8.5%.
But the more interesting figure may be the number of diagnostic tests being ordered.
The same research estimates that Vietnam generated approximately 180 million diagnostic test orders in 2025.
By 2031, annual test orders are projected to reach 260 million.
That means approximately 80 million additional diagnostic test orders every year compared with the 2025 baseline.
These figures are industry estimates and forecasts, not audited national laboratory statistics. Nevertheless, they illustrate the potential scale of Vietnam’s diagnostic services market.
For investors, the question is not simply whether Vietnam needs more laboratories.
It is whether the country’s growing demand for diagnostic testing will encourage the development of larger, more efficient laboratory networks.
The opportunity may not be to build another independent laboratory. It may be to build the platform that connects multiple laboratories together.
Vietnam’s Diagnostic Laboratory Market: US$1.12 Billion in 2025
Vietnam’s healthcare industry is undergoing structural changes that could support sustained demand for diagnostic services.
These include greater healthcare utilisation, an increasing burden of chronic diseases, expanding preventive screening and growing demand for more specialised medical investigations.
Laboratory testing plays a central role in each of these areas.
Patients managing diabetes, cardiovascular disease and other chronic conditions often require repeated biochemical and haematological investigations.
Preventive healthcare programmes rely on laboratory testing to identify potential medical problems before symptoms become severe.
Cancer diagnosis and treatment may require histopathology, immunohistochemistry, molecular diagnostics and other specialised investigations.
As access to healthcare improves, the demand for these services can increase.
Ken Research estimates that Vietnam’s diagnostic laboratory market will expand from US$1.12 billion in 2025 to US$1.83 billion in 2031, representing approximately US$710 million in additional annual market revenue.
Importantly, the forecast reflects two potential sources of growth.
The first is an increase in testing volume.
The second is a shift toward more sophisticated diagnostic services that can generate higher revenue per test.
This distinction matters because laboratory industry growth is not determined by testing volume alone. The type and complexity of testing also influence revenue and profitability.
Vietnam Could Generate 260 Million Diagnostic Test Orders Annually by 2031
The projected increase in diagnostic testing volume provides another perspective on the market.
According to Ken Research, Vietnam’s annual diagnostic test orders could increase from 180 million in 2025 to approximately 260 million in 2031.
That represents roughly 44% growth in annual testing volume over six years.
A larger volume of laboratory testing creates demand for equipment, reagents, consumables, trained personnel and laboratory infrastructure.
However, it also creates opportunities to organise diagnostic services more efficiently.
Consider two possible operating models.
In the first model, individual laboratories independently purchase equipment, maintain specialised personnel and develop their own testing capabilities.
This approach may work well for routine testing when local demand is sufficient.
But it can become expensive when each laboratory attempts to provide a broad range of specialised investigations despite relatively low testing volumes.
In the second model, laboratories operate within a larger network.
Routine tests remain available locally where appropriate, while selected specialised investigations are referred to reference laboratories serving multiple locations.
This structure can help distribute testing volumes across shared infrastructure.
It may improve equipment utilisation, reduce unnecessary duplication and expand access to specialised diagnostic services.
The economic advantage depends on sufficient testing volume, efficient specimen transportation and consistent quality management.
Nevertheless, the underlying principle is straightforward.
A laboratory network can potentially generate more value from existing infrastructure by serving multiple healthcare providers rather than relying on a single laboratory’s customer base.
Why Laboratory Networks Could Become More Important in Vietnam
Diagnostic laboratories are capital-intensive businesses.
Modern laboratory operations require more than analytical instruments.
They also depend on laboratory information systems, quality assurance, equipment maintenance, reliable reagent supply and qualified technical personnel.
Specialised diagnostic services introduce additional requirements.
Histopathology needs tissue processing facilities, staining systems and experienced pathologists.
Immunohistochemistry requires appropriate instruments, validated antibodies and specialist interpretation.
Molecular diagnostics can require advanced testing platforms, trained personnel and strict contamination controls.
For smaller laboratories, maintaining every capability independently may not be economically efficient.
A laboratory with substantial routine testing volume may still have insufficient demand to justify investing in certain low-volume specialised services.
A larger network can organise these capabilities differently.
One laboratory may focus on routine testing and specimen collection.
Another facility may provide advanced molecular diagnostics.
A specialised pathology centre may handle tissue diagnosis, immunohistochemistry and complex clinical consultations.
Each location contributes to a wider diagnostic system without necessarily duplicating every technical capability.
This model is often described as a hub-and-spoke laboratory network.
It can offer economies of scale, but successful implementation requires reliable specimen logistics, appropriate clinical oversight and effective information sharing.
Not every test should be centralised. Time-sensitive investigations and tests requiring immediate clinical decisions may need to remain close to the patient.
The opportunity lies in determining which services benefit from local delivery and which can be performed more efficiently through shared facilities.
Labcorp and Quest Diagnostics Demonstrate the Potential of Laboratory Networks
Some of the world’s largest diagnostic laboratory companies already operate variations of this model.
Their financial results illustrate the scale that diagnostic networks can achieve, although their markets and operating environments differ substantially from Vietnam.
In February 2026, Labcorp reported US$13.95 billion in revenue for the 2025 financial year, compared with US$13.01 billion in 2024.
The company also reported that it had signed or completed 13 transactions involving health systems and regional or local laboratories during 2025.
These transactions formed part of its ongoing strategy to expand laboratory partnerships and diagnostic services.
Labcorp also continued investing in specialised testing, including oncology, women’s health, neurology and autoimmune conditions.
Quest Diagnostics reported US$11.04 billion in 2025 revenue, representing an 11.8% increase over the previous year.
Quest operates an extensive network of diagnostic services and continues to develop relationships with hospitals, healthcare systems and medical practitioners.
Neither company’s success can be attributed solely to acquisitions.
Their operating models also depend on established clinical relationships, technological investment, specimen logistics, quality management and the ability to process large testing volumes.
Nevertheless, their scale demonstrates an important characteristic of the diagnostic industry.
Laboratory companies can grow by connecting healthcare providers, testing infrastructure and specialised medical capabilities within an integrated network.
Vietnam is clearly a different market from the United States.
Its healthcare financing arrangements, laboratory regulations, reimbursement systems and market structure are different.
But the fundamental business question is similar.
Can laboratories operate more effectively when selected infrastructure and technical capabilities are shared?
Why Histopathology Could Be a Valuable Part of Vietnam’s Laboratory Investment Market
Routine laboratory testing represents an important foundation for diagnostic networks.
However, specialised pathology may offer a different type of strategic value.
Histopathology is essential for diagnosing many cancers and other diseases through the microscopic examination of tissue samples.
Unlike some routine laboratory tests, histopathology cannot be fully automated through analytical instruments.
It requires qualified medical specialists to interpret tissue findings and establish diagnoses.
Complex cases may also require immunohistochemistry, molecular testing and consultation with subspecialists.
Building these capabilities takes time.
A laboratory cannot simply purchase additional equipment and immediately reproduce the expertise of an established pathology team.
It must develop appropriate clinical personnel, diagnostic workflows, quality systems and referral relationships.
This creates potential barriers to entry.
For larger laboratory groups, acquiring or partnering with an established histopathology provider could offer access to specialist expertise that would otherwise take years to develop.
Digital pathology may further support this model by enabling remote case review and specialist consultation, subject to clinical validation and applicable regulatory requirements.
However, specialist capabilities do not automatically translate into attractive financial performance.
Investors must still examine operating costs, medical staffing, referral concentration, quality assurance and the capital required for future expansion.
The strategic value of histopathology lies in the combination of medical expertise, technical infrastructure and established clinical relationships.
Could Laboratory Consolidation Accelerate in Vietnam?
Vietnam’s diagnostic industry includes hospital laboratories, independent diagnostic providers and laboratories serving individual clinics or specialist medical practices.
These businesses perform different functions and operate under different commercial arrangements.
Some may have sufficient testing volume and financial resources to develop advanced diagnostic capabilities independently.
Others may benefit from partnerships or referral relationships with specialised providers.
As diagnostic demand expands, several forms of industry consolidation could become increasingly relevant.
Larger operators may acquire established laboratories to expand geographic coverage.
Independent laboratories may cooperate with reference centres to access advanced testing without duplicating specialised infrastructure.
Hospitals may develop outsourcing arrangements for selected investigations.
Investors may establish diagnostic platforms that bring together complementary laboratory businesses under shared operating and quality systems.
Such consolidation could support investment in technology, specialist personnel and laboratory information systems.
However, acquisitions are not automatically beneficial.
Poor integration can damage referral relationships, disrupt laboratory operations and undermine medical quality.
The commercial success of any diagnostic network ultimately depends on whether it delivers reliable services to healthcare providers and patients.
AsiaLabs: Building a Platform for Laboratory Investment and Expansion
The potential development of larger diagnostic networks provides the strategic context for AsiaLabs.
AsiaLabs’ stated investment thesis focuses on developing and investing in laboratory businesses, including Anapath and Nguyễn Hoàng, while exploring opportunities for partnerships and expansion across Vietnam.
Rather than viewing each laboratory as an isolated business, the strategy considers how complementary capabilities could form part of a broader diagnostic platform.
A network may combine established local relationships with specialised testing infrastructure, medical expertise and shared operational resources.
Anapath and Nguyễn Hoàng form part of this stated development and investment approach.
The opportunity is not simply to increase the number of laboratories within a group.
It is to identify where collaboration can improve technical capabilities, expand access to specialist diagnostics and create a more efficient operating structure.
Potential benefits could include coordinated laboratory investment, broader referral relationships, improved access to specialised personnel and selected shared support functions.
Any expansion would still require careful financial assessment, regulatory compliance, independent clinical governance and protection of diagnostic quality.
The objective is to develop a sustainable laboratory business platform rather than pursue acquisitions solely for scale.
The Next Investment Opportunity May Be the Network, Not the Individual Laboratory
Vietnam’s diagnostic laboratory market could reach US$1.83 billion by 2031, according to current industry forecasts.
The projected increase from 180 million to 260 million annual diagnostic test orders suggests that the country’s laboratory infrastructure may need to support significantly greater testing demand.
But the industry’s future may not depend exclusively on building more standalone laboratories.
As testing becomes more specialised, the ability to connect laboratories, medical expertise and technical infrastructure could become increasingly valuable.
International diagnostic companies have demonstrated that laboratory networks can achieve substantial commercial scale.
Whether comparable consolidation develops in Vietnam will depend on market conditions, regulatory requirements, clinical relationships and investor execution.
For AsiaLabs, the investment thesis is based on this potential transition.
The opportunity is not merely to own laboratories. It is to develop a connected diagnostic platform capable of supporting laboratory businesses, specialist medical services and long-term expansion across Vietnam.
As Vietnam’s diagnostic market evolves, the companies best positioned for growth may be those that combine local clinical relationships with the capabilities of a larger network.